Johnson & Johnson Family of Companies
NEWS
A 3-judge panel questioned the legitimacy of Johnson & Johnson’s plan to form a subsidiary company with the purpose of absorbing legal liabilities from talc-related lawsuits.
Hard times are forcing biopharma companies to extend their runways as they try to eke out every cent of value from their capital.
Five years after joining Johnson & Johnson as head of research and development, Mathai Mammen is leaving abruptly to seek other opportunities outside the company.
BioSpace takes a look at some of the recent legal battles and settlements related to the opioid epidemic across the industry.
Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.
Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.
While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.
Genmab A/S is seeking a new arbitration ruling against Janssen seeking $405 million-plus interest in accrued milestone payments for Darzalex Faspro.
GSK reported positive headline data from a pre-specified efficacy interim analysis of the Phase III trial of its RSV vaccine.
JOBS
IN THE PRESS